Metabolize

Metabolize is a science-first consumer health and biotechnology company focused on developing products to address obesity, manage glucose levels, and support long-term weight management. Founded in 2024, the company leverages its proprietary Precision Metabolite Technology, which is based on exclusively licensed research from Stanford Medicine led by Dr. Jonathan Long. Metabolize's lead product, NATLEAN, is a synergistic formulation of N-acetyltaurine (NAT) and taurine designed to help individuals transitioning off GLP-1 therapies by reducing food noise and regulating appetite through the GFRAL receptor pathway. The company is also developing MetaPair, a non-GLP-1 weight loss alternative for individuals who are GLP-1 intolerant or ineligible.